Printer Friendly

PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS ANNOUNCE THE FORMATION OF PERISIS: A STRATEGIC ALLIANCE FOR OLIGONUCLEOTIDE MANUFACT. TECHNOLOGIES

 CARLSBAD, Calif., and CAMBRIDGE, Mass., March 1 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) and PerSeptive Biosystems, Inc. (NASDAQ: PBIO) jointly announced today that they have signed a letter of intent covering the formation of a strategic alliance, PerIsis, pursuing the development of novel tools for the manufacture of oligonucleotide therapeutics. The collaboration will focus on the application of PerSeptive's proprietary Perfusion Chromatography(R) technology for the purification, analysis and synthesis of oligonucleotides.
 Under the terms of the arrangement, PerSeptive will have the option to commercialize novel purification, analysis and synthesis products developed by this venture. The companies have also agreed to a bilateral royalty arrangement on each company's sales of certain oligonucleotide-related products. Finalization of these arrangements is subject to the execution of definitive agreements and other customary conditions.
 Isis and PerSeptive will focus on developing novel purification protocols to reduce the time required for purification, improve levels of purity, increase yield of oligonucleotide product and lower production costs. Isis and PerSeptive will also conduct research on the use of PerSeptive's POROS(R) media as supports for the large-scale synthesis of oligonucleotides.
 Oligonucleotide therapeutics have, in recent years, been shown to inhibit the production of hundreds of gene products in laboratory settings and to have attractive pharmacological properties in animals. ISIS 2105, for the treatment of human papillomavirus, is the first oligonucleotide to be tested in human beings and is currently in pivotal Phase II human clinical trials.
 Stanley T. Crooke, M.D., Ph.D., president and chief executive officer of Isis, commented on the strategic alliance: "In our preliminary work, we have already seen the positive impact that PerSeptive's products and technologies can potentially have on our manufacturing processes. Significant reductions in the time required for the development of purification and analytical methods as well as substantial improvements in purification productivity have already been achieved. We were attracted to PerSeptive as a partner because of both its existing technology as well as its unique strengths in providing novel solutions to our types of challenges."
 Commenting on the strategic alliance, Noubar B. Afeyan, Ph.D., president and chief executive officer of PerSeptive, stated: "The oligonucleotide medicinal chemistry, drug discovery and development expertise at Isis will contribute to the development and validation of new products to support the manufacturing of oligonucleotide drugs. Isis is the leader in oligonucleotide drug discovery and development. It has the most advanced oligonucleotide drug in development, the deepest product pipeline and the broadest basic research program. Isis is an ideal partner for PerSeptive in the development of applications of PerSeptive's technologies and products to the oligonucleotide field."
 Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic products based on proprietary oligonucleotide analogs. Isis has a broad oligonucleotide research program, has multiple compounds in preclinical development and its first olignucleotide-based drug, ISIS 2105, is in Phase II clinical trials.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography, ImmunoDetection(tm) and Rational Surface Design(tm).
 -0- 3/1/93
 /CONTACT: Jacqueline G. Siegel, Ph.D., chief financial officer of Isis Pharmaceuticals, 619-931-9200; Robert A. Fein, vice president and chief financial officer of PerSeptive Biosystems, 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems; Isis Pharmaceuticals ST: Massachusetts, California IN: MTC SU: JVN

DJ -- NE004 -- 1173 03/01/93 07:34 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:600
Previous Article:SYMBOL TECHNOLOGIES ANNOUNCES INTEGRATION OF THE IBM INVENTORY MANAGEMENT FOR STORES SYSTEM WITH THE SYMBOL SPECTRUM ONE NETWORK
Next Article:CAMDEV ARRANGES REFINANCING AND SIGNS FINAL LEASING AGREEMENT ON JOURNAL TOWERS
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS SUBMITS DRUG MASTER FILE WITH FDA COVERING POROS CHROMATOGRAPHY MEDIA
PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS SIGN FINAL AGREEMENT TO FORM PERISIS
PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL
PERSEPTIVE BIOSYSTEMS ANNOUNCES FILING OF REGISTRATION STATEMENT RELATING TO PERSEPTIVE TECHNOLOGIES II CORP.
PERSEPTIVE BIOSYSTEMS CREATES NEW EXECUTIVE POST
PERSEPTIVE BIOSYSTEMS COMMENCES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS ANNOUNCES PLANNED STAFF REDUCTIONS
PerSeptive Biosystems Announces a Breakthrough Application of Its PNA Technology in Genetic Analysis
PerSeptive Biosystems Reports Fourth Quarter And Fiscal 1997 Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters